Clinical Trial Update: A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants [Phase 3]

View source ↗

Summary

A Phase 3 bioequivalence and efficacy study of MB-102 (Relmapirazin) in Chinese participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Diseases
• Kidney Failure
• Kidney Injury

Drugs mentioned

• MB-102

Snippet

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Conditions: Kidney Diseases, Kidney Injury | Phase 3 | Status: COMPLETED